The ongoing Phase 1 trial at City of Hope Medical Center aims to evaluate the safety and tolerability of TGFβR2KO/IL13Rα2 CAR T-cell therapy in patients with recurrent or progressive high-grade glioma, specifically glioblastoma and IDH-mutant astrocytoma. The trial's focus on a genetically modified autologous CAR T-cell approach positions it within the rapidly evolving CAR T-cell therapy market, which has seen significant investment and interest due to its potential to address unmet medical needs in oncology. Given the high incidence of glioblastoma and the limited treatment options available, successful outcomes could lead to substantial market opportunities. The collaboration with the National Cancer Institute (NCI) enhances credibility and may facilitate regulatory pathways. However, the competitive landscape includes established CAR T therapies and emerging candidates targeting similar pathways, necessitating a robust differentiation strategy.